Preferred Skills, Qualifications, or Technical Proficiencies:
\nRequirements:
\nThe pay range that the Company reasonably expects to pay for this position is $140,000 - $155,000; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
\nApplicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link.
\nCorcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
\nPlease visit our website at: https://www.corcept.com/
\nCorcept is an Equal Opportunity Employer
\nCorcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.
\nFull-Time
Develops cortisol modulators for medical conditions
$140k - $155k/yr
Senior
Houston, TX, USA
Required to travel up to 100% of the time, including up to 40% overnight travel.
Upload your resume to see how it matches 3 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is an FDA-approved medication for Cushing's syndrome, a condition caused by excessive cortisol. Corcept stands out from competitors by having discovered over 1,000 selective cortisol modulators and by heavily investing in research and development to create new treatments. The company's goal is to expand its product offerings while also providing educational resources to improve patient care and understanding of cortisol-related disorders.
Company Size
201-500
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.
Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.
Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.